Spotlight Therapeutics

Spotlight Therapeutics is an early-stage biotechnology startup that aims to revolutionize therapeutics through in vivo gene editing. Founded in December 2017 by Alex Marson (UCSF), Jacob Corn (UC Berkeley), and Patrick Hsu (Salk Institute), it has received $36.50M Series B investment from prominent investors including GV, Emerson Collective, Magnetic Ventures, EPIQ Capital Group, GordonMD Global Investments, and Team Builder Ventures. The company's focus on oncology involves using engineered nucleases to edit genes in targeted disease organs, potentially altering or deactivating the gene product. Spotlight Therapeutics is rapidly expanding its team for cutting-edge research and preclinical development, including protein engineering, gene editing, immuno-oncology, and in vivo safety studies. With its headquarters in the United States, Spotlight Therapeutics offers an opportunity to be part of the next generation of gene editing therapeutics in a dynamic and stimulating environment.